Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study

被引：0

作者：

Kuemmel, Sherko ^{[1
,2
]}

Schmid, Peter ^{[3
]}

Harbeck, Nadia ^{[4
]}

Takahashi, Masato ^{[5
]}

Untch, Michael ^{[6
]}

Boileau, Jean-Francois ^{[7
]}

Cortes, Javier ^{[8
,9
]}

McArthur, Heather ^{[10
]}

Dent, Rebecca ^{[11
]}

O'Shaughnessy, Joyce ^{[12
]}

Pusztai, Lajos ^{[13
]}

Foukakis, Theodoros ^{[14
,15
]}

Park, Yeon Hee ^{[16
]}

Hui, Rina ^{[17
,18
]}

Cardoso, Fatima ^{[19
]}

Denkert, Carsten ^{[20
,21
]}

Zhu, Yalin ^{[22
]}

Pan, Wilbur ^{[22
]}

Karantza, Vassiliki ^{[22
]}

Fasching, Peter A. ^{[23
]}

机构：

[1] Kliniken Essen Mitte, Breast Unit, Essen, Germany

[2] Charite Univ Med Berlin, Dept Gynecol Breast Ctr, Berlin, Germany

[3] Queen Mary Univ London, Barts Canc Inst, London, England

[4] LMU Univ Hosp, Breast Ctr, Munich, Germany

[5] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan

[6] Helios Klinikum Berlin Buch, Breast Canc Ctr, Berlin, Germany

[7] McGill Univ, Jewish Gen Hosp Segal Canc Ctr, Montreal, PQ, Canada

[8] Quiron Grp, Int Breast Canc Ctr, Pangaea Oncol, Barcelona, Spain

[9] Univ Europea Madrid, Madrid, Spain

[10] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA

[11] Duke Natl Univ Singapore Med Sch, Natl Canc Ctr Singapore, Singapore, Singapore

[12] Baylor Univ, Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA

[13] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA

[14] Karolinska Inst, Solna, Sweden

[15] Karolinska Univ Hosp, Breast Canc Ctr, Karolinska Comprehens Canc Ctr, Solna, Sweden

[16] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[17] Westmead Hosp, Westmead Breast Canc Inst, Sydney, NSW, Australia

[18] Univ Sydney, Sydney, NSW, Australia

[19] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal

[20] Philipps Univ Marburg, Inst Pathol, Marburg, Germany

[21] Univ Hosp Marburg, Marburg, Germany

[22] Merck & Co Inc, Rahway, NJ USA

[23] Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany

来源：

ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1462344

引用

页码：S295 / S296

页数：2

共 50 条

[41] Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer
Rugo, Hope
Schmid, Peter
Nowecki, Zbigniew
Cescon, David
Im, Seock-Ah
Yusof, Mastura
Gallardo, Carlos
Iwata, Hiroji
Barrios, Carlos
Loi, Sherene
Zhou, Xuan
Zhang, Xiaoli
Pan, Wilbur
Karantza, Vassiliki
Cortes, Javier
CANCER RESEARCH, 2024, 84 (09)
[42] Additional Efficacy Endpoints From the Phase 3 KEYNOTE-355 Study of Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as First-Line Therapy for Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 12
[43] ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non-small cell lung cancer (mNSCLC)
Hui, Rina
Munteanu, Mihaela
Zhao, Yufan
Luo, Yiwen
Samkari, Ayman
Garassino, Marina Chiara
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[44] Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Im, Seock-Ah
Cortes, Javier
Cescon, David W.
Yusof, Mastura Md
Iwata, Hiroji
Masuda, Norikazu
Takano, Toshimi
Huang, Chiun-Sheng
Chung, Chi-Feng
Tsugawa, Koichiro
Park, Yeon Hee
Matsumoto, Koji
Inoue, Kenichi
Kwong, Ava
Loi, Sherene
Fu, Wei
Pan, Wilbur
Karantza, Vassiliki
Rugo, Hope S.
Schmid, Peter
NPJ BREAST CANCER, 2024, 10 (01)
[45] KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
Monk, Bradley J.
Colombo, Nicoletta
Tewari, Krishnansu Sujata
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
De Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Keefe, Stephen Michael
Lorusso, Domenica
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A420 - A420
[46] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
Colombo, N.
Dubot, C.
Lorusso, D.
Caceres, V.
Hasegawa, K.
Shapira-Frommer, R.
Tewari, K. S.
Salman, P.
Hoyos, E.
Yanez, E.
Gumus, M.
De Mendoza, M. Olivera Hurtado
Samouelian, V.
Castonguay, V.
Arkhipov, A.
Toker, S.
Li, K.
Keefe, S. M.
Monk, B. J.
ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
[47] KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Monk, Bradley J.
Colombo, Nicoletta
Tewari, Krishnansu Sujata
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
de Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Keefe, Stephen Michael
Lorusso, Domenica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[48] Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
Cortes, Javier
Cescon, David W.
Rugo, Hope S.
Nowecki, Zbigniew
Im, Seock-Ah
Yusof, Mastura Md
Gallardo, Carlos
Lipatov, Oleg
Barrios, Carlos Henrique
Perez-Garcia, Jose
Iwata, Hiroji
Masuda, Norikazu
Otero, Marco Torregroza
Gokmen, Erhan
Loi, Sherene
Guo, Zifang
Zhou, Xuan
Karantza, Vassiliki
Pan, Wilbur
Schmid, Peter
CANCER RESEARCH, 2022, 82 (04)
[49] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
Cortes, Javier
Guo, Zifang
Karantza, Vassiliki
Aktan, Gursel
CANCER RESEARCH, 2017, 77
[50] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Shitara, Kohei
Van Cutsem, Eric
Bang, Yung-Jue
Fuchs, Charles
Wyrwicz, Lucjan
Lee, Keun-Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol
Lee, Jeeyun
Castro, Hugo Raul
Mansoor, Wasat
Braghiroli, Maria Ignez
Karaseva, Nina
Caglevic, Christian
Villanueva, Luis
Goekkurt, Eray
Satake, Hironaga
Enzinger, Peter
Alsina, Maria
Benson, Al
Chao, Joseph
Ko, Andrew H.
Wainberg, Zev A.
Kher, Uma
Shah, Sukrut
Kang, S. Peter
Tabernero, Josep
JAMA ONCOLOGY, 2020, 6 (10) : 1571 - 1580

← 1 2 3 4 5 →